Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL420154 | 0.78 | HSP90AA1 (0.40) | HSP90AA1HSP90AB1 | |
| SCHEMBL421221 | 0.78 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1 | |
| SCHEMBL15089018 | 0.72 | HSP90AA1 (0.62) | HSP90AA1HSP90AB1 | |
| SCHEMBL15472989 | 0.66 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1 | |
| SCHEMBL27787363 | 0.64 | HSP90AA1 (0.33) | HSP90AA1HSP90AB1 | |
| SCHEMBL10345244 | 0.64 | HTR2C (0.30) | — | |
| SCHEMBL421095 | 0.63 | HSP90AA1 (0.52) | HSP90AA1HSP90AB1 | |
| SCHEMBL421467 | 0.63 | HSP90AA1 (0.39) | HSP90AA1HSP90AB1 | |
| SCHEMBL421469 | 0.63 | HSP90AA1 (0.51) | HSP90AA1HSP90AB1 | |
| SCHEMBL15472990 | 0.61 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130171105-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2013-07-04 | — | — | US | disclosed |
| US-20130171105-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR | SYNTA PHARMACEUTICALS CORP. (US) | 2013-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130171105-A1 | CANCER THERAPY USING A COMBINATION OF A HSP90 INHIBITORY COMPOUND AND A TOPOISOMERASE II INHIBITOR | TOP2A, HSP90AB1, HSP90AB2P | HSP90AA1 4/4885HSP90AB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.